Literature DB >> 16801665

Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis.

J T Chen1, D L Collins, H L Atkins, M S Freedman, A Galal, D L Arnold.   

Abstract

The authors measured brain atrophy in nine patients undergoing immunoablation and autologous hematopoietic stem cell transplantation for multiple sclerosis. From baseline to 1 month after treatment, atrophy was 10 times faster than before treatment. A patient with non-CNS lymphoma showed comparable acute brain atrophy after analogous therapy. These observations suggest that brain atrophy after immunoablation may not be due entirely to the resolution of edema but may be related to chemotoxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16801665     DOI: 10.1212/01.wnl.0000219816.44094.f8

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  Escalating immunotherapy of multiple sclerosis.

Authors:  Peter Rieckmann; Anthony Traboulsee; Virginia Devonshire; Joel Oger
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

2.  Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

Authors:  Amer Awad; Olaf Stüve
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

3.  Multiple sclerosis: Hematopoietic stem cell transplantation: hope and hype.

Authors:  Martin Stangel
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

Review 4.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 5.  Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Authors:  Carolina A Rush; Heather J MacLean; Mark S Freedman
Journal:  Nat Rev Neurol       Date:  2015-06-02       Impact factor: 42.937

Review 6.  MRI in multiple sclerosis: current status and future prospects.

Authors:  Rohit Bakshi; Alan J Thompson; Maria A Rocca; Daniel Pelletier; Vincent Dousset; Frederik Barkhof; Matilde Inglese; Charles R G Guttmann; Mark A Horsfield; Massimo Filippi
Journal:  Lancet Neurol       Date:  2008-07       Impact factor: 44.182

Review 7.  Emerging therapies for multiple sclerosis.

Authors:  Paolo A Muraro; Bibiana Bielekova
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 8.  Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.

Authors:  Dimitrios Karussis; Panayiota Petrou
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

9.  A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis.

Authors:  M A Rocca; T Mondria; P Valsasina; M P Sormani; Z H Flach; P A Te Boekhorst; G Comi; R Q Hintzen; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-20       Impact factor: 3.825

10.  Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.

Authors:  E Ghione; N Bergsland; M G Dwyer; J Hagemeier; D Jakimovski; D P Ramasamy; D Hojnacki; A A Lizarraga; C Kolb; S Eckert; B Weinstock-Guttman; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-06       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.